Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

Kristi McIntyre, Joyce O'Shaughnessy, Lee Schwartzberg, Stefan Glück, Erhan Berrak, James X. Song, David Cox, Linda T. Vahdat

Research output: Contribution to journalArticlepeer-review

38 Scopus citations

Fingerprint Dive into the research topics of 'Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences